Gerard Kelly MD MEd FRCS (ORL-HNS) FRCS (Ed) ENT surgeon, Leeds
PRECISION TRIAL : MRI to help diagnose prostate cancer · First author: Veeru Kasivisvanathan,...
1
38% TRUS Random Biopsy MRI Targeted Biopsy No MRI TRUS Random Biopsy ( 10/12 cores) Significant Cancer CANCER DETEC TION RATE K OELIS SOLUTION ALL OWS MRI + Targeted biopsy (4 cores) MRI Negative : No Biopsy PRECISION * TRI AL : MRI to help diagnose prostate cancer POPULA TION : 500 patients / 23 centers ( 6 K OELIS) Mean Age : 64 Median PSA: 6.7 Abnormal DRE 2 : 15% MRI - = 28% 28% Unnecessary Biopsy Avoided MRI += 72% Go on Targeted Biopsy Go on Surveillance of significant cancer of insignificant cancer 46% more detection 56% less detection 3 times less biopsy cores Less complications & side effects INFORMED DECISION-MAKING HIGH PRECISION MRI BEFORE BIOPSY MRI T ARGETED BIOPSY TRUS MRI TRUS MRI * PRostate E valuation f or Clinically Important disease: Sampling using Image-guidance Or Not? First author: Veeru Kasivisvanathan, University College, L ondon S tudy Chai r: Caroline Moor e MD FRCS and Mark Embe rton, University College Hospital L ondon and University College L ondon PERSONALIZED PATIENT CARE QUANTITATIVE DIAGNOSIS MRI TARGETED BIOPSY 3D PROSTATE MAPPING 26% 22% Insignificant Cancer 9% © KOELIS 2018 - KINF3000 APRIL 2018
Transcript of PRECISION TRIAL : MRI to help diagnose prostate cancer · First author: Veeru Kasivisvanathan,...
38%
TRUS Random Biopsy MRI Targeted Biopsy No MRITRUS Random Biopsy ( 10/12 cores)
Significant Cancer
CANCER DETECTION RATE
KOELIS SOLUTION ALLOWS
MRI + Targeted biopsy (4 cores)
MRI Negative : No Biopsy
PRECISION* TRIAL : MRI to help diagnose prostate cancer
POPULATION : 500 patients / 23 centers ( 6 KOELIS)Mean Age : 64 Median PSA: 6.7 Abnormal DRE2: 15%
MRI - = 28%
28% Unnecessary Biopsy Avoided
MRI += 72% Go on Targeted Biopsy
Go on Surveillance of significant cancer
of insignificant cancer
46% more detection
56% less detection
3 times less biopsy coresLess complications & side effects
INFORMED DECISION-MAKING HIGH PRECISION
MRI BEFORE BIOPSY MRI TARGETED BIOPSY
TRUS MRI TRUS MRI
*PRostate Evaluation for Clinically Important disease: Sampling using Image-guidance Or Not?
First author: Veeru Kasivisvanathan, University College, London Study Chair: Caroline Moore MD FRCS and Mark Emberton,
University College Hospital London and University College London
PERSONALIZED PATIENT CARE QUANTITATIVE DIAGNOSIS
MRI TARGETED BIOPSY 3D PROSTATE MAPPING
26%
22%
Insignificant Cancer
9%
© K
OE
LIS
20
18
- K
INF
30
00
AP
RIL
20
18
